Business Context and Reporting Period
BioAge Labs, Inc. (BIOA) is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The company is headquartered in Emeryville, California, and is classified as an emerging growth company and a smaller reporting company. This summary covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $2.8 million | $1.5 million |
| Total Operating Expenses | $28.1 million | $17.9 million |
| Net Loss | $(22.3) million | $(12.9) million |
| Net Loss Per Share (Basic & Diluted) | $(0.52) | $(0.36) |
| Cash, Cash Equivalents, and Marketable Securities | $384.9 million | $257.5 million (Cash only) |
| Accumulated Deficit | $(355.7) million | $(265.7) million |
| Net Cash Used in Operating Activities | $(24.0) million | $(17.4) million |
| Net Cash Provided by Financing Activities | $123.7 million | $(1.5) million |
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased 91% year-over-year to $2.8 million, driven by increased effort under the Novartis collaboration agreement.
- Expense Increase: Total operating expenses rose 57% to $28.1 million. Research and development (R&D) expenses increased 84% to $20.4 million, primarily due to the completion of the Phase 1 SAD/MAD trial for lead candidate BGE-102 and preparation for Phase 2 trials. General and administrative expenses increased 14% to $7.7 million.
- Capital Raise: The company completed an underwritten public offering in January 2026 and exercised the underwriters' option in February 2026, generating approximately $123.6 million in net proceeds. This significantly improved liquidity compared to the prior period.
- Debt Repayment: The company repaid its term loan in full upon maturity on April 1, 2026. As of March 31, 2026, the remaining principal balance was $0.5 million.
Guidance, Outlook, and Risks
- Clinical Progress: In April 2026, the company reported positive Phase 1 results for BGE-102, showing an 86% median reduction in hsCRP at both 60 mg and 120 mg doses with a favorable safety profile. The company plans to initiate a Phase 2 dose-ranging trial for cardiometabolic disease in mid-2026 and a Phase 1b/2a trial for diabetic macular edema (DME) in mid-2026.
- Liquidity Outlook: Management estimates that existing cash, cash equivalents, and marketable securities ($384.9 million) are sufficient to fund operations and capital expenses through 2029.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital to achieve profitability, reliance on third-party manufacturers (including potential supply chain disruptions related to geopolitical tensions), and ongoing securities litigation regarding the former product candidate azelaprag (currently on appeal).
Investor Verification Checklist
- Verify the timeline and enrollment status for the planned Phase 2 trials of BGE-102 in cardiometabolic disease and DME.
- Confirm the status of the securities class action appeal regarding azelaprag and potential financial exposure.
- Monitor the company's cash burn rate relative to the $384.9 million liquidity position to validate the 2029 runway estimate.
- Review the terms of the Novartis collaboration agreement for future milestone payment triggers and revenue recognition policies.
- Assess the impact of the BIOSECURE Act on the company's reliance on Chinese manufacturers (e.g., WuXi Apptec) for drug substance and product.